Related Experiment Video

Updated: Jun 8, 2026

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

Emerging therapeutic targets and agents for glioblastoma therapy - part I

Hui-Wen Lo

    Anti-Cancer Agents in Medicinal Chemistry
    |October 13, 2010
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
    09:02

    Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

    Published on: September 27, 2024

    Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
    11:15

    Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

    Published on: September 1, 2018

    Related Experiment Videos

    Last Updated: Jun 8, 2026

    Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
    04:46

    Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

    Published on: February 24, 2023

    Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
    09:02

    Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

    Published on: September 27, 2024

    Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
    11:15

    Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

    Published on: September 1, 2018

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    SERINC2-mediated phosphatidylserine remodeling activates protrusion-localized AXL signaling to promote brain metastasis.

    Cell reports·2026

    RET receptor tyrosine kinase promotes breast cancer metastasis to the brain and RET inhibitors pralsetinib and selpercatinib suppress breast cancer brain metastases.

    Cell death & disease·2026

    Breast Cancer-Derived Extracellular Vesicle miR-425-5p (miR-425) Promotes Brain Metastasis via Activating Astrocytes Through the Novel miR-425-ZNF24-CCL8 Signaling Axis.

    International journal of molecular sciences·2026

    RET Receptor Tyrosine Kinase Promotes Breast Cancer Metastasis to the Brain and RET Inhibitors Pralsetinib and Selpercatinib Suppress Breast Cancer Brain Metastases.

    bioRxiv : the preprint server for biology·2025

    Extracellular vesicle-derived miR-425-5p (miR-425) activates astrocytes in the brain to promote breast cancer brain metastasis via the novel miR-425-ZNF24-CCL8 signaling axis.

    bioRxiv : the preprint server for biology·2025

    Targeting tGLI1, a novel mediator of tumor therapeutic resistance, using Ketoconazole sensitizes glioblastoma to CDK4/6 therapy and chemoradiation.

    bioRxiv : the preprint server for biology·2025

    In Silico Evaluation of Annonaceous Acetogenins as Potential HER2 and MELK Inhibitors for Targeted Cancer Therapy.

    Anti-cancer agents in medicinal chemistry·2026

    Validating the Role of TRAF2 and Nck-Interacting Kinase as a Potential Target in Colorectal Cancer Progression: A Deeper Insight from Expression Profiling and Epigenetic Analysis.

    Anti-cancer agents in medicinal chemistry·2026

    The Role of Biomarkers in Personalized Treatment of Gastrointestinal Cancers.

    Anti-cancer agents in medicinal chemistry·2026

    Wogonoside Suppresses the Self-renewal Ability of Glioma Stem Cells via Down-regulating AKT/ZEB1 Signaling Pathway.

    Anti-cancer agents in medicinal chemistry·2026

    Targeting Metabolic Dysfunctions in Cancer through Nanoparticles: Advances in Therapeutic Delivery.

    Anti-cancer agents in medicinal chemistry·2026

    Research Progress on the Antitumor Effects of Isorhamnetin (ISO) and Its Molecular Mechanisms.

    Anti-cancer agents in medicinal chemistry·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us